Previous 10 | Next 10 |
2024-03-30 12:13:00 ET The Health Care Select Sector SPDR Fund ETF ( NYSEARCA: XLV ), tracking the healthcare companies under S&P 500, rose 8.32% in the first quarter of 2024, lagging slightly behind the broader S&P 500 index which rose 10.16%.... Read the full article...
2024-03-28 09:44:31 ET Summary Insulet Corporation, the maker of the Omnipod Insulin Management System, provides essential services to a patient group of 10 million diabetes patients and has experienced significant growth over the past decade. The company's wearable and discrete s...
2024-03-26 09:29:13 ET More on Tandem Diabetes Care Tandem Diabetes Care, Inc. (TNDM) Q4 2023 Earnings Call Transcript Tandem Diabetes Care GAAP EPS of -$0.46 misses by $0.19, revenue of $196.8M misses by $6.05M Seeking Alpha’s Quant Rating on Tandem Diabetes ...
2024-03-22 09:25:36 ET More on markets Nasdaq, S&P, and Dow futures notice limited movement while yields tick down Dividend Roundup: JPMorgan Chase, Starbucks, CVS Health, Mondelez, and more S&P 500 and 20% of its holdings flash overbought signals, according ...
2024-03-20 06:46:19 ET More on Insulet Insulet: An Interesting, Yet Expensive, Story Insulet Omnipod 5 insulin pump bests conventional delivery systems Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M Seeking Alpha’s Qu...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effecti...
2024-03-08 08:43:37 ET More on Insulet Insulet Corporation (PODD) Q4 2023 Earnings Call Transcript Insulet: An Interesting, Yet Expensive, Story Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M Insulet Q4 2023 Earnings Preview...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported ou...
Conducted in the United States and France, the OP5-003 Trial is the first Omnipod 5 study to include international participants. The OP5-003 Trial Presentation and Insulet Symposium will convey the importance of automated insulin delivery (AID) technology as Standard of Care. ...
2024-03-04 10:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-04-23 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial mar...